| ID Source | ID |
|---|---|
| PubMed CID | 12471 |
| CHEMBL ID | 1894620 |
| SCHEMBL ID | 657760 |
| MeSH ID | M0131975 |
| Synonym |
|---|
| ec 211-219-8 |
| j7ic72n9b0 , |
| 4-12-00-01281 (beilstein handbook reference) |
| unii-j7ic72n9b0 |
| nsc2114 |
| 2,6-trichloroaniline |
| s-trichloroaniline |
| aniline,4,6-trichloro- |
| nsc-2114 |
| 634-93-5 |
| wln: zr bg dg fg |
| benzenamine,4,6-trichloro- |
| 1-amino-2,6-trichlorobenzene |
| 2,6-trichlorophenylamine |
| aniline, 2,4,6-trichloro- |
| benzenamine, 2,4,6-trichloro- |
| AC-907/25014096 |
| 2,4,6-trichloroaniline |
| NCGC00090846-01 |
| brn 0879568 |
| nsc 2114 |
| hsdb 2654 |
| einecs 211-219-8 |
| sym-trichloroaniline |
| ccris 601 |
| 2,4,6-trichlorobenzenamine |
| 2,4,6-trichlorophenylamine |
| 1-amino-2,4,6-trichlorobenzene |
| inchi=1/c6h4cl3n/c7-3-1-4(8)6(10)5(9)2-3/h1-2h,10h |
| 2,4,6-trichloroaniline, technical, >=98.0% (hplc) |
| AC-10672 |
| T0375 |
| AKOS000119904 |
| A1751 |
| NCGC00090846-02 |
| dtxcid401379 |
| NCGC00258616-01 |
| tox21_201063 |
| cas-634-93-5 |
| dtxsid6021379 , |
| FT-0609847 |
| PS-6295 |
| 2,4,6-trichloroaniline [hsdb] |
| SCHEMBL657760 |
| W-104909 |
| CHEMBL1894620 |
| F0001-1722 |
| mfcd00007663 |
| 2,4,6-trichloroaniline, pestanal(r), analytical standard |
| 2,4,6-trichloraniline |
| AM10760 |
| 2,3,6-trichloroaniline;2,4,6-trichloroaniline;benzenamine, 2,4,6-trichloro-;aniline, 2,4,6-trichloro-;2,3,6-trichloroaniline 2,4,6-trichloroaniline benzenamine, 2,4,6-trichloro- aniline, 2,4,6-trichloro- |
| 2,4,6-trichloroaniline 1000 microg/ml in toluene |
| H11251 |
| Q27281312 |
| EN300-19778 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.8900 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.2239 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 53.6526 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 17.6952 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 21.5517 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 47.8180 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 75.7864 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||